Related Experiment Video
Updated: Dec 31, 2025
03:37
Intravitreal Injections in the Ovine Eye
Published on: July 5, 2022
3.8K
Intravitreal Injection of Anti-VEGF Antibody Induces Glomerular Endothelial Cells Injury
F Touzani1,2, C Geers3, A Pozdzik1,2
1Department of Nephrology and Dialysis, Centre Hospitalier Universitaire, Hospital Brugmann, Brussels, Belgium.
Case Reports in Nephrology
|January 15, 2020
Summary
Intravitreal bevacizumab (anti-VEGF) can cause kidney injury by damaging glomerular endothelial cells, leading to proteinuria and reduced kidney function. This case highlights a potential risk even with local anti-VEGF therapy.
Area of Science:
- Nephrology
- Ophthalmology
- Oncology
Background:
- Anti-VEGF agents are crucial in cancer and ocular disease therapy.
- Systemic use can cause renal microangiopathy; local use is considered safer.
- Bevacizumab is an anti-VEGF monoclonal antibody used systemically and locally.
